Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - tamoxifen citrate, quantity: 30.4 mg (equivalent: tamoxifen, qty 20 mg) - tablet, uncoated - excipient ingredients: magnesium stearate; croscarmellose sodium; maize starch; mannitol - treatment of breast cancer. genox is indicated for the treatment of breast cancer. primary reduction of breast cancer risk. genox is indicated for the primary reduction of breast cancer risk in women either at moderately increased risk (lifetime breast cancer risk 1.5 to 3 times the population average) or high risk (lifetime breast cancer risk greater than 3 times the population average).

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - tamoxifen citrate, quantity: 15.2 mg (equivalent: tamoxifen, qty 10 mg) - tablet, uncoated - excipient ingredients: maize starch; magnesium stearate; croscarmellose sodium; mannitol - treatment of breast cancer. genox is indicated for the treatment of breast cancer. primary reduction of breast cancer risk. genox is indicated for the primary reduction of breast cancer risk in women either at moderately increased risk (lifetime breast cancer risk 1.5 to 3 times the population average) or high risk (lifetime breast cancer risk greater than 3 times the population average).

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - ibuprofen, quantity: 200 mg; paracetamol, quantity: 500 mg - tablet, film coated - excipient ingredients: titanium dioxide; povidone; purified water; microcrystalline cellulose; hypromellose; purified talc; magnesium stearate; crospovidone; colloidal anhydrous silica; pregelatinised maize starch; polysorbate 80; polyvinyl alcohol; macrogol 3350; mica - temporary relief of acute (short term) pain and / or inflammation associated with headache, migraine headache, tension headache, sinus pain, toothache, dental procedures, backache, muscular aches and pains, period pain, sore throat, tennis elbow, rheumatic pain and arthritis, and the aches and pains associated with colds and flu. reduces fever.

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - ibuprofen, quantity: 200 mg; codeine phosphate hemihydrate, quantity: 12.8 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; microcrystalline cellulose; colloidal anhydrous silica; pregelatinised maize starch; titanium dioxide; hypromellose; macrogol 400 - for temporary relief of acute moderate pain and inflammation in patients over the age of 12 years (see also section contraindications and special warnings and precuations for use - paediatric use)

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - ibuprofen, quantity: 200 mg; codeine phosphate hemihydrate, quantity: 12.8 mg - tablet, film coated - excipient ingredients: lactose monohydrate; purified water; maize starch; glyceryl behenate; colloidal anhydrous silica; magnesium stearate; titanium dioxide; hypromellose; macrogol 6000 - amcal ibuprofen plus codeine is used for temporary relief of acute moderate pain and inflammation in patients over the age of 12 years.

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - codeine phosphate hemihydrate, quantity: 12.8 mg; ibuprofen, quantity: 200 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; lactose monohydrate; purified water; magnesium stearate; glyceryl behenate; maize starch; titanium dioxide; hypromellose; macrogol 6000 - for temporary relief of acute moderate pain and inflammation

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - ibuprofen, quantity: 400 mg - tablet, film coated - excipient ingredients: sodium lauryl sulfate; povidone; colloidal anhydrous silica; macrogol 6000; stearic acid; croscarmellose sodium; titanium dioxide; purified water; purified talc; hypromellose; microcrystalline cellulose; lactose monohydrate - for the temporary relief of pain and/or inflammation associated with headache, migraine headache, tension headache, sinus pain, toothache, dental procedures, backache, muscular aches and pains, period pain, sore throat, tennis elbow, arthritis, rheumatic pain and aches and pains associated with colds and flu. reduces fever.

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - codeine phosphate hemihydrate, quantity: 12.8 mg; ibuprofen, quantity: 200 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; croscarmellose sodium; pregelatinised maize starch; microcrystalline cellulose; titanium dioxide; hypromellose; macrogol 400 - for temporary relief of acute moderate pain and inflammation in patients over the age of 12 years

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - ibuprofen, quantity: 400 mg - tablet, film coated - excipient ingredients: titanium dioxide; macrogol 6000; croscarmellose sodium; purified water; povidone; sodium lauryl sulfate; stearic acid; colloidal anhydrous silica; lactose monohydrate; microcrystalline cellulose; purified talc; hypromellose - for the temporary relief of pain and/or inflammation associated with headache, migraine headache, tension headache, sinus pain, toothache, dental procedures, backache, muscular aches and pains, period pain, sore throat, tennis elbow, arthritis, rheumatic pain and aches and pains associated with colds and flu. reduces fever.

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - tamoxifen citrate, quantity: 30.4 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; lactose monohydrate; gelatin; titanium dioxide; maize starch; macrogol 300; hypromellose; magnesium stearate - treatment of breast cancer nolvadex-d is indicated for the treatment of breast cancer. primary reduction of breast cancer risk nolvadex-d is indicated for the primary reduction of breast cancer risk in women either at moderately increased risk (lifetime breast cancer risk 1.5 to 3 times the population average) or high risk (lifetime breast cancer risk greater than 3 times the population average).